ARTICLE | Clinical News
Melinta reports Phase I data for acne candidate radezolid
October 13, 2017 12:35 AM UTC
Melinta Therapeutics Inc. (New Haven, Conn.) reported data from a Phase I trial in 10 patients with mild to moderate acne vulgaris showing that twice-daily topical radezolid (RX-1741) for 4 weeks was well tolerated with minimal systemic absorption...
BCIQ Company Profiles
BCIQ Target Profiles